Log in
Enquire now
Spiderwort

Spiderwort

A biotechnology company using tissue engineering to create biomaterials for repairing and regenerating the human body.

OverviewStructured DataIssuesContributors

Contents

spiderwortbio.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biology
Biology
Regenerative medicine
Regenerative medicine
0
Technology
Technology
Biotechnology
Biotechnology
Location
Canada
Canada
Ottawa
Ottawa
0
Gatineau
Gatineau
0
B2X
B2B
B2B
0
CEO
‌
Charles M. Cuerrier
0
Founder
‌
Charles M. Cuerrier
0
‌
Andrew E. Pelling
0
AngelList URL
angel.co/spiderwort
Number of Employees (Ranges)
11 – 500
Full Address
283, boulevard Alexandre-Taché (F3006) Gatineau, Québec J9A 1L80
7 Bayview Road, Ottawa, Ontario K1Y 2C5, CA0
Investors
Box One Ventures
Box One Ventures
0
Groupe Roski
Groupe Roski
0
Horizons Ventures
Horizons Ventures
K5 Global
K5 Global
BoxOne Ventures
BoxOne Ventures
Founded Date
2015
Total Funding Amount (USD)
13,200,000
CFO
‌
Scott Jarvis
0
Latest Funding Type
Series A
Series A
Wellfound ID
spiderwort
Country
Canada
Canada
0

Other attributes

Company Operating Status
Active

Spiderwort is a biotechnology company using tissue engineering to create biomaterials for repairing and regenerating the human body that is headquartered in Ottawa, Ontario and was founded in 2015 by Andrew Pelling and Charles M. Cuerrier. The company is using plant derived cellulose to create biomaterial scaffolding architectures that are biocompatible and capable of inducing angiogenesis (blood vessel generation), promote cell infiltration, promote cell growth, promote tissue repair, and promote tissue reconstruction.

Funding
Angel

On June 10, 2019 Spiderwort announced raising CA$500,000 from the CEO of Assent Compliance Andrew Waitman. At the time of announcing their angel funding round the company also announced Dane Bedward, an executive fellow with Mistral Ventures Partners, and Peter Morand, former CEO and president of Natural Sciences and Engineering Research Council of Canada and the founding CEO of the Canadian Science and Technology Growth Fund, will be joining the company's board of directors.

Seed

On May 27, 2020 Spiderwort announced raising $2.5 million in seed funding from Horizons Ventures (lead investors), Capital Angel Network, Break Off Capital, and Anges Quebec. The company plans on using their seed funding to develop a treatment for spinal cord injuries using plant-based materials. Spiderwort also named Dane Benward, the former president of Genzyme Canada and executive fellow of Mistral Venture Partners, the chairman of Spiderworts board of directors. Patrick Zhang from Horizons Ventures also joined the board of Spiderwort at the time of seed funding.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Spiderwort

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.